Sun Pharma withdraws multiple eye-drop products in India over contamination concerns, telling distributors to halt sales and return stock
2 Aug, 04:33 IST · Plays out within days · 2 sources
India's biggest drugmaker has pulled several eye-drop brands off shelves after a contamination scare, which dents its reputation and sales in eye care and hands a short-term opening to rival eye-drop makers like Ajanta Pharma and FDC.
Key facts
What the reporting establishes, before any reading of it.
- Sun Pharma withdrew several eye-drop products as a precautionary measure over contamination concerns, including Depopred, Brinolar (BKC FREE), Brinzotim, Lotepred, Nepalact and Toba-F.
- Distributors were told to halt sales and return stock; the company says it is working to restore availability.
- The affected products treat glaucoma and eye infections, so patients need substitutes immediately.
- This follows a separate July 2026 US recall of about 2.5 million bottles of India-made eye drops after a contamination scare, so regulatory attention on Indian ophthalmic manufacturing is already elevated.
How the news spreads
Step by step — from the first companies it hits to whole sectors.
Who it hits first
- Sun Pharma has told distributors to stop selling and return stock of several eye-drop brands — Depopred, Brinolar (BKC FREE), Brinzotim, Lotepred, Nepalact and Toba-F — so those products earn nothing until supply is restored.
- The withdrawn products treat glaucoma and eye infections, conditions where patients cannot pause treatment, so demand transfers to competitors immediately rather than being deferred.
- A contamination event raises the odds of regulatory inspection at the manufacturing site, which can hold up other products from the same plant.
Who may gain
- Ajanta Pharma, which has one of India's strongest branded ophthalmic ranges and is the natural first substitute.
- FDC, which sells ophthalmic and anti-infective medicines and picks up a smaller share of the switched prescriptions.
- Cipla and other large branded-formulation makers pick up marginal volume, though history shows they often trade down with Sun Pharma on the news rather than up.
Along the supply chain
Downstream
Pharmacy chains and distributors must physically return stock, taking a working-capital hit and losing a fast-moving category from their shelves. Hospitals and eye clinics switch protocols to rival brands. Patients on glaucoma therapy face a substitution they did not choose, which is the reason the demand transfer is immediate rather than deferred.
Upstream
The active pharmaceutical ingredient and contract manufacturers supplying Sun Pharma's withdrawn ophthalmic lines lose orders until production restarts, and the sterile-manufacturing site involved may face inspection that delays other products made there. Suppliers to Ajanta Pharma and FDC see the mirror-image pickup in orders for the same molecules.
Where demand moves
Business
Prescriptions for glaucoma and eye-infection drops cannot be postponed, so doctors and pharmacists substitute another brand within days. That demand goes to Ajanta Pharma first, then to FDC, Cipla and Indoco in the ophthalmic segment. Sun Pharma loses not just this month's sales but some of the prescription habit, because doctors who successfully switch a stable patient often do not switch back. Upstream, the contract manufacturers and active-ingredient suppliers feeding Sun Pharma's ophthalmic line lose orders, while those feeding Ajanta and FDC gain them.
Capital
Money moves out of Sun Pharma into the smaller ophthalmic-exposed names on a share-shift thesis — Ajanta Pharma rose 1.91%, 8.48% and 2.17% on three past Sun Pharma recall days. But there is a competing flow that history shows is often stronger: some investors sell Indian pharma broadly on a contamination headline, treating it as a manufacturing-quality question, which is why Cipla fell on three of the four past recall dates. Net capital movement is therefore small and concentrated in the direct ophthalmic substitutes.
How it spreads across sectors
Healthcare
Short-term share shift within Indian ophthalmics from Sun Pharma to Ajanta Pharma and FDC, plus a broader sentiment drag on Indian pharma manufacturing quality.
Pharma
Renewed regulatory attention on sterile ophthalmic manufacturing, following the separate July 2026 US recall of about 2.5 million bottles of India-made eye drops.
When it plays out
Immediate
Sun Pharma typically falls 0.7-2.8% on the day of a recall announcement, while direct ophthalmic competitors are flat to up — Ajanta Pharma gained on three of four past occasions.
Medium term
History says this reverses: Sun Pharma was higher one month after three of the four past recalls (+3.06%, +5.22%). The exception was November 2014, when the recall coincided with wider quality problems. The lasting risk is not this recall but whether it signals a systemic sterile-manufacturing issue that draws US FDA attention.
Short term
Over the following weeks watch whether the drug regulator escalates from a voluntary withdrawal to a formal action, and whether Sun Pharma restores supply. Sun Pharma was down 3.1-5.6% a week after two of the four past recalls.